Hansoh Pharmaceutical Gr 주식 (OTC: HNSPF)

에 대한 최신 뉴스 Hansoh Pharmaceutical Gr (OTC:HNSPF) 주식

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Technicals

Trading Ideas

HNSPF

PSNL

머크 앤드 컴퍼니(NYSE:MRK)의 주가가 목요일에 소폭 반등세를 보이고 있지만 여전히 약세에서 벗어나지 못한 형국이다. 주가가 결국 95.00달러 정도 수준에 도달하면 주가가 반전되어 상승할 가능성이 높다. 차트에서 볼 수 있듯이 이는 11월 말에 일어난 일이다. 이러한 이유로 우리 기술 분석 팀은 이를 오늘의 주식으로 선정했다.

오늘의 주식: 머크의 하락 추세는 어디에서 끝나나?

HANSOH PHARMACEUTICAL GP by Hansoh Pharmaceutical Group Co Ltd.

Hansoh Pharmaceutical Group Co Ltd

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Outperform and raises the price target from $163 to $170.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on KKR, Raises Price Target to $170

2025 Outlook&nbsp;
For the full year 2025, the company expects:
<ul>
<li>Net yields (in constant currency) approximately 4.2 percent higher than record 2024 levels based on continued strength in demand.</li>
<li>Adjusted cruise costs excluding fuel per ALBD (in constant currency) up approximately 3.7 percent compared to 2024, in part due to higher dry-dock days, higher advertising expense and operating costs for the company's new exclusive destination, Celebration Key.</li>
<li>Adjusted net income of approximately $2.3 billion, over 20 percent higher than 2024.</li>
<li>Adjusted EBITDA of approximately $6.6 billion, up approximately $500 million compared to 2024. Adjusted EBITDA per ALBD to reach its 2026 SEA Change target one year in advance.</li>
<li>Adjusted ROIC of approximately 11.7 percent.</li>
</ul>

Earnings

Guidance

For 2025, Carnival Projects 4.2% Increase In Net Yields, 3.7% Rise In Adjusted Cruise Costs Per ALBD, $2.3B In Adjusted Net Income, $6.6B In Adjusted EBITDA, And An Adjusted ROIC Of 11.7%

Canaccord Genuity analyst Kingsley Crane maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and raises the price target from $2.8 to $3.

Canaccord Genuity Maintains Hold on BlackBerry, Raises Price Target to $3

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) with a Market Perform and lowers the price target from $19 to $18.

Keefe, Bruyette & Woods Maintains Market Perform on Invesco, Lowers Price Target to $18

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>AMD</li>
<li>MSTR</li>
<li>NVO</li>
<li>QQQ</li>
<li>CORN</li>
<li>$BTC</li>
<li>RKLB</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

AAPL

CORN

MSTR

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 20, 2024 (Via Swaggy Stocks)

RBC Capital analyst Paul Treiber reiterates BlackBerry (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BB#TSX">BB</a>) with a Sector Perform and maintains C$3.25 price target.

Reiteration

TSX:BB

RBC Capital Reiterates Sector Perform on BlackBerry, Maintains C$3.25 Price Target

Offerings

QNRX

Quoin Pharmaceuticals Prices $6.8M Public Offering Of 15,111,110 American Depository Shares And Series F Warrants  At $0.45 Per ADS And Series F And Series G Warrants

WIIM

AMGN

Amgen shares are trading higher. Weight-loss related stocks are up on Friday following weaker-than-expected data from competitor Lilly.

RBC Capital analyst Paul Treiber reiterates BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Sector Perform and maintains $3.25 price target.

RBC Capital Reiterates Sector Perform on BlackBerry, Maintains $3.25 Price Target

Barclays analyst Jared Shaw maintains Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) with a Equal-Weight and raises the price target from $84 to $88.

Barclays Maintains Equal-Weight on Prosperity Bancshares, Raises Price Target to $88

$19.6 million in cash and cash equivalents as of September 30, 2024
Dramatically reduced cash burn rate expected

SNPX

Synaptogenix Board Of Directors Forms Special Committee To Explore Value Creation Opportunities

BNED

Barnes & Noble Education Launches $40M At-The-Market Equity Offering Program

Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.08 by 75 percent. This is a 300 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $5.938 billion which beat the analyst consensus estimate of $5.932 billion by 0.10 percent. This is a 10.02 percent increase over sales of $5.397 billion the same period last year.

Earnings Beats

Carnival Q4 2024 Adj. EPS $0.14 Beats $0.08 Estimate, Sales $5.938B Beat $5.932B Estimate

MMSI

Merit Medical Secures FDA Approval For WRAPSODY Cell-Impermeable Endoprosthesis, Extending Life-Saving Treatment For Dialysis Patients With U.S. Commercialization Set For 2025

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) with a Market Perform and raises the price target from $152 to $190.

IBKR

Keefe, Bruyette & Woods Maintains Market Perform on Interactive Brokers Gr, Raises Price Target to $190

Barclays analyst Jared Shaw maintains Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) with a Overweight and raises the price target from $110 to $115.

BPOP

Barclays Maintains Overweight on Popular, Raises Price Target to $115

RBC Capital analyst Brian Abrahams maintains Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Sector Perform and lowers the price target from $4 to $1.5.

APLT

RBC Capital Maintains Sector Perform on Applied Therapeutics, Lowers Price Target to $1.5

Barclays analyst Jared Shaw maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Overweight and raises the price target from $26 to $27.

Barclays Maintains Overweight on Old National, Raises Price Target to $27

Comedian Jerry Seinfeld is having the last laugh. New York is back in business. During the pandemic, when The New York Times published an article questioning if New York was over, Seinfeld hit back at the hand-wringing skeptics with a Times article of his own, &#8220;So You Think New York Is &#8216;Dead&#8217; (It&#8217;s not).&#8221; He was right. Recent numbers show that the Big Apple&#8217;s commercial real estate numbers are back to pre-pandemic levels as workers return to the office en masse, breathing life into surrounding businesses and residential real estate.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
<h2 class="wp-block-heading">The Squeeze For Leases</h2>
The New York Post reports that several major companies have difficulty finding office space. It cites Singapore-based sovereign wealth fund Temasek, which leases 27,000 square feet at the Seagram Building at 375 Park Ave. and wanted to expand its footprint but could not. This pattern is cropping up throughout the city, with commercial data and analytics companies unable to keep up with the pace of lease fillings.&nbsp;
Bryant Park Corporation president Dan Biederman told The Post: &#8220;Almost all of the landlords in our area are telling prospective tenants, &#8216;Sorry, we have no space left.'&#8221;
Commercial real estate broker and the CEO of the New York Tri-State Region of <a href="https://www.benzinga.com/insights/analyst-ratings/24/12/42361972/unveiling-4-analyst-insights-on-cbre-group">CBRE</a>, the world&#8217;s largest commercial real estate services firm, Mary Ann Tighe said on a recent podcast, &#8220;If you are a tenant of 100,000 square feet or greater, you should have done your deal already. By the time we get to 2027, you&#8217;re going to have a problem.&#8221;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
To emphasize the situation, Tighe said that of the 2.4 million square feet of new commercial space to be completed by the end of 2026, 79% is already pre-leased. The numbers are not affected by rental conversions of older buildings into residential ones because, as outdated spaces, they were not suitable for modern offices.&nbsp;
Cushman &amp; Wakefield broker Mark Weiss stated: &#8220;Some tenants have a false perception that the market&#8217;s open, there&#8217;s nobody in the offices – but in fact, it&#8217;s tighter than it was in 2019.&#8221;
<h2 class="wp-block-heading">WeWork Dominates Splashy Commercial Real Estate Deadlines</h2>
Recent splashy commercial real estate headlines have been filled with news of major Manhattan tenant leases. Among the most eye-catching was <a href="https://www.benzinga.com/news/24/05/39078002/wework-has-a-new-boss-adam-neumanns-no-drama-successor-anant-yardi-to-take-control-of-bankrupt-co-wo">WeWork</a> and <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42458086/jeff-bezos-had-more-money-than-all-bitcoins-put-together-just-4-years-ago-this-was-the-moment-when-it-changed">Amazon</a> partnering on a deal for over 300,000 square feet at 330 W. 34th St. Amazon&#8217;s back-to-work mandate for its employees has seen the giant tech company fill space throughout New York City at other WeWork locations, including at 1440 Broadway, a few blocks south of Times Square. Amazon also has office space at Brookfield Properties&#8217; Five Manhattan West at 450 W. 33rd St., which occupies more than 285,000 square feet, according to CoStar data.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.
&#8220;This collaboration underscores our commitment to sustainable growth and meeting the diverse needs of our clients where they need us most,&#8221; the WeWork spokesperson told CoStar News, adding the property is located in &#8220;one of the city&#8217;s most dynamic and rapidly evolving&#8221; commercial hubs.
Law firm Ropes &amp; Gray&#8217;s 430,000-square-foot lease at 1285 Ave. of the Americas last month marks one of Manhattan&#8217;s largest office leases this year.&nbsp;
<h2 class="wp-block-heading">Tech&#8217;s Titanic Manhattan Office Footprint&nbsp;</h2>
Tech is all over New York. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42513402/apples-2025-bull-case-can-it-deliver-without-riding-the-ai-wave">Apple </a>expanded to nearly 398,000 square feet at Penn 11. At the beginning of 2024, Google opened its $2.1 billion office at St. John&#8217;s Terminal. Bloomberg LP recently signed a renewal and expansion lease at SL Green Realty Corp.&#8217;s 919 Third Ave., a 1.5 million-square-foot, 47-story office tower in Manhattan, bringing its footprint to 924,876 square feet at the high-rise. As of May 2024, Bloomberg occupied 2.1 million square feet of Manhattan office space.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
<h2 class="wp-block-heading">Return To Work</h2>
The return-to-office mandate implemented by many major companies is spurring the headline-grabbing Manhattan office deals. Amazon&#8217;s C.E.O. Andy Jassy recently demanded that all employees return to the office five days a week. At the same time, execs at other companies, such as JPMorgan Chase&#8217;s Jamie Dimon and Goldman Sachs&#8217;s David Solomon, made a similar decision.
&#8220;Clearly a return to office mentality is bringing a lot more people back and forcing some of these existing tenants to come back into the market where they had laid off space because they thought they were going to have a more robust hybrid work environment and now they&#8217;re bringing the bodies back,&#8221; Steven Durels, SL Green executive vice president, said on the company&#8217;s third-quarter earnings call in October.
Full offices have allowed small businesses in Manhattan to make a roaring trade after years in the doldrums following the pandemic, including many food delivery services.&nbsp;
&#8220;Over the past two years, over 400 new businesses have started in Chinatown and Two Bridges, helping to create almost 3,000 jobs,&#8221; said Melissa Pumphrey, with New York City&#8217;s Economic Development Corporation.
There has also been a surge in residential leases in Manhattan and home prices in cities nationally as RTO mandates kick in, forcing workers to leave rural areas and the suburbs.
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>

Real Estate

Ignore New York At Your Peril: NYC Office Market Hits Overdrive, Breathing Life Into The City's Business And Real Estate

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 15 years by 6.78% on an annualized basis producing an average annual return of 18.37%. Currently, First Citizens BancShares has a market capitalization of $28.97 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 15 years ago, it would be worth $1,255.04 today based on a price of $2070.94 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734704108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug candidates that treat symptoms of schizophrenia.

Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO

Week In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIO

Amgen posts late-stage win for Uplizna in immune-mediated disorder

Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma

Merck enters obesity drug race in pact with Chinese pharma Hansoh

Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers

ASLN

AZNCF

GPCR

MTVA

REGMF

SLNCF

SOLTF

TERN

VKTX

WUXAY

WUXIF

Hansoh Pharmaceutical Gr

머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)의 주가가 목요일에 소폭 반등세를 보이고 있지만 여전히 약세에서 벗어나지 못한 형국이다.
주가가 결국 95.00달러 정도 수준에 도달하면 주가가 반전되어 상승할 가능성이 높다. 차트에서 볼 수 있듯이 이는 11월 말에 일어난 일이다. 이러한 이유로 우리 기술 분석 팀은 이를 <a href="https://kr.benzinga.com/?s=%EC%98%A4%EB%8A%98%EC%9D%98+%EC%A3%BC%EC%8B%9D+" target="_blank" rel="noopener">오늘의 주식</a>으로 선정했다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-700197" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" alt="Merck" width="1024" height="557" /></figure>
머크에서 많은 뉴스가 나왔다.
고급 암 유전자 검사 제공업체인 퍼스널리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)가 머크로부터 5천만 달러의 지분 투자를 받았다고 발표했다. 거래가 마무리되면 머크는 퍼스널리스의 16.5%를 소유하게 된다.
또한 머크은 <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">수익성 높은 비만 시장에 진입</a>한다고 발표했다. 중국 바이오텍 기업 한소제약(Hansoh Pharmaceutical Group Company Limited)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)로부터 GLP-1 수용체 경구 투여제의 라이센스를 획득했다.
머크의 차트는 몇 가지 간단하지만 가치 있는 기술적 분석 교훈을 제공한다. 저항선이었던 가격 수준이 지지선으로 변환될 수 있다. 또한 지지선까지 주가가 하락하면 반등하는 경향이 있다.
추가 읽기: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">테바 제약, 위장 관련 질환 2상 후보 데이터 발표</a>
119.40달러는 2023년 5월 저항선이었다. 당시 매도한 일부 투자자들은 가격이 곧바로 하락하자 좋은 결정을 내렸다고 생각했다.
하지만 2024년 1월 저항선을 돌파하고 주가가 상승했다. 이때 일부 매도자들은 실수를 했다고 생각하고 매도한 가격에 주식을 다시 사기로 결정했다.
그래서 주가가 2024년 3월에 다시 119.40달러 수준으로 하락하자 이들은 매수 주문을 넣었다. 이 주문의 대량 집중이 이전의 저항선 가격에서 지지선으로 형성되었다.
유사한 행동이 111.00달러 수준에서도 발생했다. 2023년 8월 저항선이었으나 2024년 8월에는 지지선이 되었다.
2022년 7월에는 95.00달러 수준이 저항선이었다. 지난달 지지선으로 전환되었고, 머크가 다시 도달하면 지지선이 될 수 있다.
이 차트에서 볼 수 있듯이, 주가가 지지선에 도달한 후 상승하는 경우도 있다. 이는 지지선을 형성한 일부 매수자들이 더 높은 가격에 팔려고 할 때 발생한다. 다른 사람이 더 높은 가격을 지불할 의사가 있다면, 매도자들은 그쪽으로 간다.
결과적으로 그들은 지불할 의사가 있는 가격을 인상한다. 다른 이들도 이를 보고 동일한 행동을 취한다. 이는 주가를 상승시키는 눈덩이 효과를 유발할 수 있으며, 머크에서도 곧 발생할 수 있다.
주가 움직임: 머크의 주식은 목요일 미국 동부 시간 오후 2시 10분에 1.16% 상승한 99.44달러에 거래되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">비트코인, 연준 회의 후 102,000달러 이상 반등; 미국 GDP 3.1% 증가, 실업 수당 청구 감소, 국채 수익률 정점 – 오늘의 주요 뉴스</a></li>
</ul>
이미지 출처: Merck.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Hansoh Pharmaceutical Gr

뉴스

에 대한 최신 뉴스 Hansoh Pharmaceutical Gr (OTC:HNSPF) 주식

목요일, 12월 19, 2024

뉴스

파트너 / 기고자

벤징가 글로벌